The Case for More Aggressive Masking in Psychedelic Trials
This Viewpoint discusses the UMBRAA (unidentifiable multidrug blinding with reduced, authorized awareness) strategy to address the masking problem in psychedelic trials.
Authors
- Kevin H. Yang (ORCID: https://orcid.org/0000-0002-1451-258X)
- Josh Woolley
- Boris D. Heifets
- Andrew Krystal
Institutions
- San Francisco VA Medical Center (US)
- University of California San Diego (US)
- Stanford University (US)
Publication Details
- Journal
- JAMA Psychiatry
- Published
- 2026-09-16
- DOI
- https://doi.org/10.1001/jamapsychiatry.2026.2858
- Primary Topic
- Psychedelics and Drug Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00